---
layout: default
title: Palivizumab
parent: 僅模型預測 (L5)
nav_order: 529
evidence_level: L5
indication_count: 10
---

# Palivizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Palivizumab: From RSV Infection Prophylaxis to Benign Neoplasm of Tongue

## One-Sentence Summary

Palivizumab is a monoclonal antibody that neutralizes the RSV fusion (F) glycoprotein, originally used to prevent respiratory syncytial virus (RSV) infection in high-risk infants. The TxGNN model predicts a possible link to **benign neoplasm of tongue**, but this prediction is backed by **0 clinical trials** and **0 publications**, and the model's own rationale flags it as likely a knowledge-graph false positive rather than a genuine mechanistic signal.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | RSV infection prophylaxis (inferred from mechanism description in the evidence pack; formal TFDA label text not yet extracted — see DG001) |
| Predicted New Indication | Benign neoplasm of tongue |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L5 |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed DrugBank mechanism-of-action data is not yet available for Palivizumab (see DG002). Based on the mechanistic description recorded alongside this prediction, Palivizumab is a monoclonal antibody directed against the RSV F glycoprotein — it works by neutralizing the virus's fusion protein to block RSV entry into respiratory epithelial cells. This is an antiviral, immunoprophylactic mechanism with no known role in cell proliferation, oncogenesis, or tumour suppression pathways.

There is no plausible mechanistic bridge between neutralizing a respiratory virus surface protein and a benign tongue neoplasm — the two are biologically unrelated systems (viral immunology vs. localized epithelial/mesenchymal tumour growth). Notably, the evidence pack's own rationale for this prediction explicitly states that the high TxGNN score is most likely driven by node-embedding proximity in the knowledge graph rather than a real biological relationship — i.e., the model itself flags this as a probable false positive.

This pattern is not isolated to rank 1: all ten of Palivizumab's top predicted indications are structurally/anatomically unrelated neoplasms and cysts (epiglottis neoplasm, cervical neuroblastoma, testicular tumour, thyroglossal duct cyst, etc.), each with an identical absence of supporting trials or literature. This consistent pattern across the full top-10 list further supports the interpretation that these are embedding-space artifacts rather than a coherent repurposing signal.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Malaysia Market Information

Palivizumab is marketed in Malaysia with 1 active registration. Registration-level detail (license number, product name, dosage form, approved indication text) has not yet been extracted from source documents — this is tracked as a blocking data gap (DG001) rather than presented here as placeholder content.

## Safety Considerations

Please refer to the package insert for safety information. (Warning, contraindication, and drug-interaction data have not yet been extracted from the TFDA label — see DG001, which is flagged as a blocking gap for safety evaluation.)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence level is L5 (model prediction only, no supporting trials or literature), and the prediction's own mechanistic rationale identifies it as a probable false positive from knowledge-graph embedding proximity rather than genuine biological plausibility. A blocking safety data gap (DG001) also prevents this candidate from entering the S1 safety screening stage.

**To proceed, the following is needed:**
- TFDA label extraction (warnings, contraindications, DDI) to close DG001 and enable S1 safety screening
- DrugBank-sourced mechanism-of-action data to close DG002 and support a rigorous mechanistic-plausibility assessment
- Independent preclinical or mechanistic evidence connecting RSV F-protein neutralization to tongue neoplasm biology before any further investment in this candidate
- Given the systematic pattern across all top-10 predictions, a review of whether this candidate set reflects a broader TxGNN embedding artifact for this drug rather than isolated noise
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

